These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19493658)

  • 21. A defect in the antioxidant defense system in schizophrenia.
    Virit O; Altindag A; Yumru M; Dalkilic A; Savas HA; Selek S; Erel O; Herken H
    Neuropsychobiology; 2009; 60(2):87-93. PubMed ID: 19776652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Clin Neuropharmacol; 2009; 32(1):6-9. PubMed ID: 19471183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of anticholinergics on positive and negative symptoms in schizophrenia.
    Tandon R; DeQuardo JR; Goodson J; Mann NA; Greden JF
    Psychopharmacol Bull; 1992; 28(3):297-302. PubMed ID: 1480733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment.
    Chua SE; Deng Y; Chen EY; Law CW; Chiu CP; Cheung C; Wong JC; Lienenkaëmper N; Cheung V; Suckling J; McAlonan GM
    Psychol Med; 2009 May; 39(5):793-800. PubMed ID: 18713487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Validation of the Temporal Experience of Pleasure Scale (TEPS) in a French-speaking environment].
    Favrod J; Ernst F; Giuliani F; Bonsack C
    Encephale; 2009 Jun; 35(3):241-8. PubMed ID: 19540410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
    Lee BH; Kim YK
    Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia.
    Liu SK; Fitzgerald PB; Daigle M; Chen R; Daskalakis ZJ
    Biol Psychiatry; 2009 Mar; 65(6):503-9. PubMed ID: 18950746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of antipsychotic medication on pain perception in schizophrenia.
    Jochum T; Letzsch A; Greiner W; Wagner G; Sauer H; Bär KJ
    Psychiatry Res; 2006 Jun; 142(2-3):151-6. PubMed ID: 16631931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.
    de Haan L; Nimwegen Lv; Amelsvoort Tv; Dingemans P; Linszen D
    Pharmacopsychiatry; 2008 Jul; 41(4):125-8. PubMed ID: 18651339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precautionary measures reduce risk of definite neuroleptic malignant syndrome in newly typical neuroleptic-treated schizophrenia inpatients.
    Shiloh R; Valevski A; Bodinger L; Misgav S; Aizenberg D; Dorfman-Etrog P; Weizman A; Munitz H
    Int Clin Psychopharmacol; 2003 May; 18(3):147-9. PubMed ID: 12702893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
    Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
    Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.
    Schwarcz G; Karajgi B; McCarthy R
    J Clin Psychopharmacol; 2009 Jun; 29(3):255-8. PubMed ID: 19440079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile.
    Pazvantoglu O; Selek S; Okay IT; Sengul C; Karabekiroglu K; Dilbaz N; Erel O
    Psychiatry Clin Neurosci; 2009 Oct; 63(5):693-700. PubMed ID: 19788631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duration of untreated psychosis and it's effect on the functional outcome in schizophrenia - preliminary results.
    Sarotar BN; Pesek MB; Agius M; Pregelj P; Kocmur M
    Psychiatr Danub; 2008 Jun; 20(2):179-83. PubMed ID: 18587288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE.
    Steiner J; Walter M; Wunderlich MT; Bernstein HG; Panteli B; Brauner M; Jacobs R; Gos T; Rothermundt M; Bogerts B
    Biol Psychiatry; 2009 Jun; 65(12):1107-10. PubMed ID: 19103440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.